[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA113658C2 - Кристалічна форма і дималеатного інгібітору тирозинкінази і способи її одержання - Google Patents

Кристалічна форма і дималеатного інгібітору тирозинкінази і способи її одержання

Info

Publication number
UA113658C2
UA113658C2 UAA201500919A UAA201500919A UA113658C2 UA 113658 C2 UA113658 C2 UA 113658C2 UA A201500919 A UAA201500919 A UA A201500919A UA A201500919 A UAA201500919 A UA A201500919A UA 113658 C2 UA113658 C2 UA 113658C2
Authority
UA
Ukraine
Prior art keywords
preparation
dymaleate
methods
crystal form
dimaleate
Prior art date
Application number
UAA201500919A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA113658C2 publication Critical patent/UA113658C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/08Malonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Кристалічна форма І дималеату (R,Е)-N-(4-(3-хлоро-4-(піридин-2-іл-метокси)-феніламіно)-3-ціано-7-етоксихінолін-6-іл)-3-(1-метилпіролідин-2-іл)пропенаміду (під назвою SHR1258 дималеат для скорочення), способи її одержання та фармацевтична композиція на її основі. Кристалічна форма І SHR1258 дималеату має добру стабільність кристала та хімічну стабільність та може бути використана при одержанні медикаментів для лікування хвороб, що пов'язані з EGFR рецептором тирозинкінази або HER-2 рецептором тирозинкінази.
UAA201500919A 2012-07-12 2013-06-04 Кристалічна форма і дималеатного інгібітору тирозинкінази і способи її одержання UA113658C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210240697.0A CN103539783A (zh) 2012-07-12 2012-07-12 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
PCT/CN2013/076717 WO2014008794A1 (zh) 2012-07-12 2013-06-04 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法

Publications (1)

Publication Number Publication Date
UA113658C2 true UA113658C2 (xx) 2017-02-27

Family

ID=49915377

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201500919A UA113658C2 (xx) 2012-07-12 2013-06-04 Кристалічна форма і дималеатного інгібітору тирозинкінази і способи її одержання

Country Status (21)

Country Link
US (1) US9309226B2 (uk)
EP (1) EP2873664B1 (uk)
JP (1) JP6170146B2 (uk)
KR (1) KR102078077B1 (uk)
CN (2) CN103539783A (uk)
AU (1) AU2013289789B2 (uk)
BR (1) BR112015000045B1 (uk)
CA (1) CA2876884C (uk)
DK (1) DK2873664T3 (uk)
ES (1) ES2656623T3 (uk)
HK (1) HK1199027A1 (uk)
HU (1) HUE037946T2 (uk)
MX (1) MX349672B (uk)
NO (1) NO2873664T3 (uk)
PL (1) PL2873664T3 (uk)
PT (1) PT2873664T (uk)
RU (1) RU2631321C2 (uk)
TW (1) TWI597277B (uk)
UA (1) UA113658C2 (uk)
WO (1) WO2014008794A1 (uk)
ZA (1) ZA201500471B (uk)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105985408B (zh) * 2015-02-12 2020-06-26 正大天晴药业集团股份有限公司 一种卡非佐米的纯化方法
CN108026059A (zh) * 2015-07-22 2018-05-11 阿纳韦克斯生命科学公司 四氢-n,n-二甲基-2,2-二苯基-3-呋喃甲胺盐酸盐的晶型,制备这样晶型的方法,及其药物组合物
RU2743014C2 (ru) * 2016-01-27 2021-02-12 Цзянсу Хэнжуй Медицин Ко., Лтд. Фармацевтическая композиция, включающая производное хинолина или его соль
HUE050255T2 (hu) * 2016-01-27 2020-11-30 Jiangsu Hengrui Medicine Co Eljárás kinolinszármazékot vagy sóját tartalmazó gyógyászati készítmény elõállítására
CN112426424A (zh) * 2016-01-28 2021-03-02 江苏恒瑞医药股份有限公司 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途
CN112645933B (zh) * 2016-03-22 2022-02-11 江苏豪森药业集团有限公司 Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用
WO2018133838A1 (zh) 2017-01-22 2018-07-26 江苏恒瑞医药股份有限公司 Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途
CN109963846A (zh) * 2017-08-07 2019-07-02 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法
CN109516976B (zh) * 2017-09-19 2022-05-27 南京圣和药业股份有限公司 取代嘧啶类pi3k抑制剂甲磺酸盐的晶型及其制备方法
KR20200078561A (ko) 2017-10-24 2020-07-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 퀴놀린 유도체를 함유하는 약학 조성물
CN110960529A (zh) * 2018-09-30 2020-04-07 江苏恒瑞医药股份有限公司 一种降低了毒性杂质含量的酪氨酸激酶抑制剂的原料药
WO2020083188A1 (zh) 2018-10-22 2020-04-30 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的一马来酸盐的晶型及其制备方法
CN111138414A (zh) * 2018-11-05 2020-05-12 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的晶型及其制备方法
TW202115027A (zh) * 2019-08-30 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 低雜質含量的酪胺酸激酶抑制劑
CN114674937B (zh) * 2020-12-24 2024-07-05 沈阳药科大学 一种马来酸长链脂肪酰胺中长链脂肪胺的测定方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101824029A (zh) * 2009-03-05 2010-09-08 厦门艾德生物医药科技有限公司 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途
CN102020639A (zh) * 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
ZA201500471B (en) 2016-10-26
EP2873664A4 (en) 2015-12-30
ES2656623T3 (es) 2018-02-27
KR102078077B1 (ko) 2020-02-17
BR112015000045B1 (pt) 2021-10-26
EP2873664B1 (en) 2017-11-01
MX2014015623A (es) 2015-06-23
CN103974949B (zh) 2015-11-25
CN103974949A (zh) 2014-08-06
US9309226B2 (en) 2016-04-12
DK2873664T3 (en) 2018-01-08
CN103539783A (zh) 2014-01-29
US20150166511A1 (en) 2015-06-18
CA2876884A1 (en) 2014-01-16
TW201402563A (zh) 2014-01-16
RU2015103065A (ru) 2016-08-27
AU2013289789B2 (en) 2017-06-29
BR112015000045A2 (pt) 2017-06-27
HUE037946T2 (hu) 2018-09-28
EP2873664A1 (en) 2015-05-20
HK1199027A1 (zh) 2015-06-19
WO2014008794A1 (zh) 2014-01-16
NO2873664T3 (uk) 2018-03-31
MX349672B (es) 2017-08-08
TWI597277B (zh) 2017-09-01
AU2013289789A1 (en) 2015-01-22
JP6170146B2 (ja) 2017-07-26
PL2873664T3 (pl) 2018-06-29
KR20150036336A (ko) 2015-04-07
RU2631321C2 (ru) 2017-09-21
CA2876884C (en) 2019-12-10
JP2015522042A (ja) 2015-08-03
PT2873664T (pt) 2018-01-24

Similar Documents

Publication Publication Date Title
UA113658C2 (xx) Кристалічна форма і дималеатного інгібітору тирозинкінази і способи її одержання
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
DK1848414T3 (da) Fremgangsmåde til behandling af gefitinib-resistent cancer
CR20150450A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
MX368833B (es) Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor.
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201591908A1 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы
BR112017024555A2 (pt) moduladores de ccr2
CR20130629A (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
MX359200B (es) Inhibidores de cinasa.
PH12014500794A1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
CR20160598A (es) Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il) amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil) pirimidino-4-carboxamida
BR112014003693A2 (pt) amino quinazolinas como inibidores de quinase
WO2016100347A3 (en) Small molecule inhibitors of egfr and pi3k
BR112014027117A2 (pt) derivados de pirazol aminopirimidina como moduladores de lrrk2 para uso no tratamento de doença de parkinson
PH12016502461A1 (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
NZ627560A (en) Heterocyclic piperazine compounds and methods for their use
WO2012122058A3 (en) Alkyne substituted quinazoline compound and methods of use
BR112015021586A2 (pt) formulações de morfina
GEP20156319B (en) Asymmetric ureas and medical uses thereof
PH12014501278A1 (en) Kinase inhibitors
MY155230A (en) Sulfoximine-substituted aniline pyrimidine derivatives as cdk inhibitors, their manufacture and use as medicine
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
EA201101207A1 (ru) Применение антагонистов рецептора nk